Phase I/II trials of 186Re-HEDP in metastatic castration-resistant prostate cancer: post-hoc analysis of the impact of administered activity and dosimetry on survival.
about
Imaging and dosimetry for radium-223: the potential for personalized treatment.Reply to 'Single high dose versus repeated bone-targeted radionuclide therapy'.Bone lesion absorbed dose profiles in patients with metastatic prostate cancer treated with molecular radiotherapy.Single high dose versus repeated bone-targeted radionuclide therapy.A radiobiological model of metastatic burden reduction for molecular radiotherapy: application to patients with bone metastases.
P2860
Phase I/II trials of 186Re-HEDP in metastatic castration-resistant prostate cancer: post-hoc analysis of the impact of administered activity and dosimetry on survival.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 21 October 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Phase I/II trials of 186Re-HED ...... ity and dosimetry on survival.
@en
Phase I/II trials of 186Re-HED ...... ity and dosimetry on survival.
@nl
type
label
Phase I/II trials of 186Re-HED ...... ity and dosimetry on survival.
@en
Phase I/II trials of 186Re-HED ...... ity and dosimetry on survival.
@nl
prefLabel
Phase I/II trials of 186Re-HED ...... ity and dosimetry on survival.
@en
Phase I/II trials of 186Re-HED ...... ity and dosimetry on survival.
@nl
P2093
P2860
P1476
Phase I/II trials of 186Re-HED ...... ity and dosimetry on survival.
@en
P2093
Antigoni Divoli
Bernadette Johnson
David P Dearnaley
Joe M O'Sullivan
Sarah J Chittenden
V Ralph McCready
P2860
P2888
P304
P356
10.1007/S00259-016-3543-X
P577
2016-10-21T00:00:00Z